Literature DB >> 20456486

Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans.

Barbara Lubsczyk1, Marietta Kollars, Gregor Hron, Paul A Kyrle, Ansgar Weltermann, Verena Gartner.   

Abstract

BACKGROUND: Microparticles (MPs) have procoagulant properties as shown in vitro and in animal models. Their role in haemostatic system activation at the site of a vascular injury in vivo in humans has not been studied.
MATERIAL AND METHODS: In a prospective randomized crossover study, 13 healthy volunteers were given 100 mg acetylsalicylic acid or placebo daily for 7 days. Number and cellular origin, expression of tissue factor (TF) and phosphatidylserine on MPs, and platelet and coagulation activation markers [beta-thromboglobulin (beta-TG), prothrombin fragment f1.2 (f1.2)] were measured in venous blood and in blood from a vascular injury (shed blood) by flow cytometry and immunoassays, respectively.
RESULTS: The number of MPs was significantly higher in shed blood than in venous blood. The majority of MPs were platelet derived. The expression of TF on MPs was low, but higher in shed blood than in venous blood. TF positive MPs were significantly higher in shed blood, which was due to an increase of MPs from platelets (PMPs). In shed blood, the number of TF expressing platelet-derived MPs correlated with beta-TG, but not with f1.2. Low dose acetylsalicylic acid did not affect shedding of PMPs, neither in venous blood nor in shed blood.
CONCLUSIONS: The release of PMPs locally at the site of platelet plug formation in humans indicates a possible role of MPs for haemostatic system activation in vivo. Low dose acetylsalicylic acid might not be strong enough to suppress shedding of PMPs in the microcirculation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456486     DOI: 10.1111/j.1365-2362.2010.02299.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

1.  Different Contribution of Monocyte- and Platelet-Derived Microvesicles to Endothelial Behavior.

Authors:  Marta Brambilla; Maria Talmon; Paola Canzano; Luigia G Fresu; Sandra Brunelleschi; Elena Tremoli; Marina Camera
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

2.  Effects of anticoagulation on markers of activation of clotting following major orthopedic surgery.

Authors:  M M Bern; D Hazel; D T Reilly; D M Adcock; L Hou
Journal:  Int J Lab Hematol       Date:  2015-05-15       Impact factor: 2.877

Review 3.  Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis.

Authors:  Lina Badimon; Rosa Suades; Eduardo Fuentes; Iván Palomo; Teresa Padró
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

4.  The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study.

Authors:  Stefan Weisshaar; Brigitte Litschauer; Sebastian Bucher; Martin Riesenhuber; Stylianos Kapiotis; Paul Alexander Kyrle; Michael Wolzt
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 5.  Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse.

Authors:  Lina Badimon; Rosa Suades; Gemma Arderiu; Esther Peña; Gemma Chiva-Blanch; Teresa Padró
Journal:  Front Cardiovasc Med       Date:  2017-12-18

Review 6.  The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.

Authors:  Justyna Rosińska; Maria Łukasik; Wojciech Kozubski
Journal:  Cardiovasc Drugs Ther       Date:  2017-12       Impact factor: 3.727

Review 7.  Platelet-Derived Extracellular Vesicles as Target of Antiplatelet Agents. What Is the Evidence?

Authors:  Francesco Taus; Alessandra Meneguzzi; Marco Castelli; Pietro Minuz
Journal:  Front Pharmacol       Date:  2019-11-08       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.